SCHEMBL14129149

SCHEMBL14129149

CCCOCCOCCOC(=O)/C(C#N)=C/c1ccc(N(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
ALDH1A1 P00352 5/20 0.57
PSMD14 O00487 1/20 0.57
DNM1 Q05193 3/20 0.52
MAPT P10636 4/20 0.51
IDE P14735 2/20 0.50
KDM4E B2RXH2 1/20 0.50
PPARG P37231 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
RAB9A P51151 1/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
APP P05067 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14129172 0.97 MEN1 (0.54) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL21457218 0.93 MEN1 (0.61) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL21457220 0.93 MEN1 (0.61) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL14701202 0.91 MEN1 (0.62) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL26382501 0.91 APP (0.56) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL2011563 0.91 APP (0.56) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL2011561 0.91 APP (0.56) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL2011560 0.91 APP (0.56) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL14129171 0.89 MEN1 (0.60) MEN1KMT2AALDH1A1PSMD14DNM1
SCHEMBL12633780 0.87 APP (0.53) MEN1KMT2AALDH1A1PSMD14DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180126008-A1 Methods Of Preparing Ophthalmic Formulations And Uses Of Same COGNOPTIX, INC. 2018-05-10 US disclosed
US-20170315137-A1 AMYLOID BINDING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-02 US disclosed
US-9551722-B2 Amyloid binding agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-01-24 US disclosed
US-20160278677-A1 Method for Measuring Fluorescence in Ocular Tissue COGNOPTIX, INC. 2016-09-29 US disclosed
US-20150177262-A1 AMYLOID BINDING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-25 US disclosed
US-20150118163-A1 Methods of Preparing Ophthalmic Formulations and Uses of Same COGNOPTIX, INC. 2015-04-30 US disclosed
US-20120302603-A1 AMYLOID BINDING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302603-A1 AMYLOID BINDING AGENTS APP, APBA1, PSEN1 MEN1 3763/4885KMT2A 4740/4885ALDH1A1 3897/4885
US-20170315137-A1 AMYLOID BINDING AGENTS APBA1, APP, PSEN1 MEN1 3531/4885KMT2A 4712/4885ALDH1A1 4267/4885
US-20160278677-A1 Method for Measuring Fluorescence in Ocular Tissue ALDH1A2, FUCA1, EYA3 MEN1 2227/4885KMT2A 4555/4885ALDH1A1 673/4885
US-20180126008-A1 Methods Of Preparing Ophthalmic Formulations And Uses Of Same PDE6G, PDE6A, F12 MEN1 2616/4885KMT2A 4187/4885ALDH1A1 1932/4885
US-20150118163-A1 Methods of Preparing Ophthalmic Formulations and Uses of Same PDE6G, PDE6A, F12 MEN1 2616/4885KMT2A 4187/4885ALDH1A1 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.